在心脏病学领域推广合理治疗，美国心血管药物杂志涵盖了心血管疾病治疗的各个方面，特别关注新和已确立的药物在治疗中的位置。 通过一系列综述和原始临床研究文章，该杂志涉及与这些疾病治疗相关的主要问题，包括主要药物类的药理学，疗效和不良反应; 新开发的药物和药物类的信息; 最新研究心血管疾病发病原因的治疗意义; 以及具体临床情况的实际管理。美国心血管药物杂志提供一系列增强功能，旨在增加杂志内容的可见性，读者数量和教育价值。每篇文章都附有关键要点摘要，向广大读者提供了时间效率高的内容概述。文章可能附有明确简明的摘要，以帮助患者，照顾者和其他人了解重要的医学进展。该杂志还提供包括幻灯片集，视频和动画等各种增强功能的选项。所有增强功能都按照同样高标准进行同行评审，就像文章本身一样。同行评审使用Editorial Manager®进行，由国际专家数据库支持。该数据库与其他Adis杂志共享。

Promoting rational therapy within the discipline of cardiology, the American Journal of Cardiovascular Drugs covers all aspects of the treatment of cardiovascular disorders, particularly the place in therapy of newer and established agents. Via a program of reviews and original clinical research articles, the journal addresses major issues relating to treatment of these disorders, including the pharmacology, efficacy and adverse effects of the major classes of drugs; information on newly developed drugs and drug classes; the therapeutic implications of latest research into the aetiology of cardiovascular disorders; and the practical management of specific clinical situations. The American Journal of Cardiovascular Drugs offers a range of additional enhanced features designed to increase the visibility, readership and educational value of the journal’s content. Each article is accompanied by a Key Points summary, giving a time-efficient overview of the content to a wide readership. Articles may be accompanied by plain language summaries to assist patients, caregivers and others in understanding important medical advances. The journal also provides the option to include various other types of enhanced features including slide sets, videos and animations. All enhanced features are peer reviewed to the same high standard as the article itself. Peer review is conducted using Editorial Manager®, supported by a database of international experts. This database is shared with other Adis journals.